Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B vs Engerix-B in Subjects 11-55 Years Old
NCT00435812Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Dec 2006
- Primary completion
- Feb 2008
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 2
01
Overview
A Phase 3 trial of Heplisav-B in hepatitis B (HBV), sponsored by Dynavax Technologies. Started Dec 2006; status: completed.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00435812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00435812.